292 related articles for article (PubMed ID: 15252839)
1. High BRAF mutation frequency does not characterize all melanocytic tumor types.
Saldanha G; Purnell D; Fletcher A; Potter L; Gillies A; Pringle JH
Int J Cancer; 2004 Sep; 111(5):705-10. PubMed ID: 15252839
[TBL] [Abstract][Full Text] [Related]
2. BRAF, NRAS and HRAS mutations in spitzoid tumours and their possible pathogenetic significance.
Da Forno PD; Pringle JH; Fletcher A; Bamford M; Su L; Potter L; Saldanha G
Br J Dermatol; 2009 Aug; 161(2):364-72. PubMed ID: 19438459
[TBL] [Abstract][Full Text] [Related]
3. NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing.
Edlundh-Rose E; Egyházi S; Omholt K; Månsson-Brahme E; Platz A; Hansson J; Lundeberg J
Melanoma Res; 2006 Dec; 16(6):471-8. PubMed ID: 17119447
[TBL] [Abstract][Full Text] [Related]
4. Mutations of the BRAF gene in benign and malignant melanocytic lesions.
Yazdi AS; Palmedo G; Flaig MJ; Puchta U; Reckwerth A; Rütten A; Mentzel T; Hügel H; Hantschke M; Schmid-Wendtner MH; Kutzner H; Sander CA
J Invest Dermatol; 2003 Nov; 121(5):1160-2. PubMed ID: 14708620
[TBL] [Abstract][Full Text] [Related]
5. Low prevalence of RAS-RAF-activating mutations in Spitz melanocytic nevi compared with other melanocytic lesions.
Indsto JO; Kumar S; Wang L; Crotty KA; Arbuckle SM; Mann GJ
J Cutan Pathol; 2007 Jun; 34(6):448-55. PubMed ID: 17518771
[TBL] [Abstract][Full Text] [Related]
6. BRAF and NRAS mutations in melanoma and melanocytic nevi.
Poynter JN; Elder JT; Fullen DR; Nair RP; Soengas MS; Johnson TM; Redman B; Thomas NE; Gruber SB
Melanoma Res; 2006 Aug; 16(4):267-73. PubMed ID: 16845322
[TBL] [Abstract][Full Text] [Related]
7. Massively parallel sequencing analysis of benign melanocytic naevi.
Lozada JR; Geyer FC; Selenica P; Brown D; Alemar B; Merghoub T; Berger MF; Busam KJ; Halpern AC; Weigelt B; Reis-Filho JS; Hollmann TJ
Histopathology; 2019 Jul; 75(1):29-38. PubMed ID: 30791119
[TBL] [Abstract][Full Text] [Related]
8. Cutaneous melanoma subtypes show different BRAF and NRAS mutation frequencies.
Saldanha G; Potter L; Daforno P; Pringle JH
Clin Cancer Res; 2006 Aug; 12(15):4499-505. PubMed ID: 16899595
[TBL] [Abstract][Full Text] [Related]
9. The BRAF and NRAS mutation prevalence in dermoscopic subtypes of acquired naevi reveals constitutive mitogen-activated protein kinase pathway activation.
Tan JM; Tom LN; Jagirdar K; Lambie D; Schaider H; Sturm RA; Soyer HP; Stark MS
Br J Dermatol; 2018 Jan; 178(1):191-197. PubMed ID: 28714107
[TBL] [Abstract][Full Text] [Related]
10. Absence of BRAF and NRAS mutations in uveal melanoma.
Cruz F; Rubin BP; Wilson D; Town A; Schroeder A; Haley A; Bainbridge T; Heinrich MC; Corless CL
Cancer Res; 2003 Sep; 63(18):5761-6. PubMed ID: 14522897
[TBL] [Abstract][Full Text] [Related]
11. NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression.
Omholt K; Platz A; Kanter L; Ringborg U; Hansson J
Clin Cancer Res; 2003 Dec; 9(17):6483-8. PubMed ID: 14695152
[TBL] [Abstract][Full Text] [Related]
12. Mutation analysis of the EGFR-NRAS-BRAF pathway in melanomas from black Africans and other subgroups of cutaneous melanoma.
Akslen LA; Puntervoll H; Bachmann IM; Straume O; Vuhahula E; Kumar R; Molven A
Melanoma Res; 2008 Feb; 18(1):29-35. PubMed ID: 18227705
[TBL] [Abstract][Full Text] [Related]
13. Frequent alterations of Ras signaling pathway genes in sporadic malignant melanomas.
Reifenberger J; Knobbe CB; Sterzinger AA; Blaschke B; Schulte KW; Ruzicka T; Reifenberger G
Int J Cancer; 2004 Apr; 109(3):377-84. PubMed ID: 14961576
[TBL] [Abstract][Full Text] [Related]
14. Activating BRAF mutations in eruptive melanocytic naevi.
Sekulic A; Colgan MB; Davis MD; DiCaudo DJ; Pittelkow MR
Br J Dermatol; 2010 Nov; 163(5):1095-8. PubMed ID: 20716222
[TBL] [Abstract][Full Text] [Related]
15. Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma.
Goel VK; Lazar AJ; Warneke CL; Redston MS; Haluska FG
J Invest Dermatol; 2006 Jan; 126(1):154-60. PubMed ID: 16417231
[TBL] [Abstract][Full Text] [Related]
16. Number of nevi and early-life ambient UV exposure are associated with BRAF-mutant melanoma.
Thomas NE; Edmiston SN; Alexander A; Millikan RC; Groben PA; Hao H; Tolbert D; Berwick M; Busam K; Begg CB; Mattingly D; Ollila DW; Tse CK; Hummer A; Lee-Taylor J; Conway K
Cancer Epidemiol Biomarkers Prev; 2007 May; 16(5):991-7. PubMed ID: 17507627
[TBL] [Abstract][Full Text] [Related]
17. Genomic aberrations in spitzoid melanocytic tumours and their implications for diagnosis, prognosis and therapy.
Wiesner T; Kutzner H; Cerroni L; Mihm MC; Busam KJ; Murali R
Pathology; 2016 Feb; 48(2):113-31. PubMed ID: 27020384
[TBL] [Abstract][Full Text] [Related]
18. NRAS and BRAF mutation frequency in primary oral mucosal melanoma.
Buery RR; Siar CH; Katase N; Gunduz M; Lefeuvre M; Fujii M; Inoue M; Setsu K; Nagatsuka H
Oncol Rep; 2011 Oct; 26(4):783-7. PubMed ID: 21750866
[TBL] [Abstract][Full Text] [Related]
19. RAS and RAF mutations in banal melanocytic aggregates contiguous with primary cutaneous melanoma: clues to melanomagenesis.
Dadzie OE; Yang S; Emley A; Keady M; Bhawan J; Mahalingam M
Br J Dermatol; 2009 Feb; 160(2):368-75. PubMed ID: 18945298
[TBL] [Abstract][Full Text] [Related]
20. BRAF and NRAS mutations in spitzoid melanocytic lesions.
Fullen DR; Poynter JN; Lowe L; Su LD; Elder JT; Nair RP; Johnson TM; Gruber SB
Mod Pathol; 2006 Oct; 19(10):1324-32. PubMed ID: 16799476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
